Stock AXSM AXSOME THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
74.76 USD +0.90% Intraday chart for Axsome Therapeutics, Inc. +0.74% -6.07%
Jun. 05 Axsome Therapeutics Says It Settled Sunosi Patent Litigation With Unichem Laboratories MT
Jun. 05 RBC Raises Price Target on Axsome Therapeutics to $130 From $127, Keeps Outperform Rating MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Axsome therapeutics settles sunosi patent litigation with unichem laboratories
AQ
Axsome Therapeutics Says It Settled Sunosi Patent Litigation With Unichem Laboratories
MT
RBC Raises Price Target on Axsome Therapeutics to $130 From $127, Keeps Outperform Rating
MT
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
GL
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
GL
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
AQ
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
GL
Axsome Therapeutics to Participate in Upcoming Investor Conferences
GL
Axsome Therapeutics to Participate in Upcoming Investor Conferences
AQ
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
GL
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
GL
Transcript : Axsome Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:00 AM
Mizuho Securities Adjusts Price Target on Axsome Therapeutics to $106 From $109, Maintains Buy Rating
MT
Axsome Therapeutics to Present at Upcoming Investor Conferences
GL
Axsome Therapeutics to Present at Upcoming Investor Conferences
AQ
Baird Adjusts Price Target on Axsome Therapeutics to $112 From $108, Maintains Outperform Rating
MT
Transcript : Axsome Therapeutics, Inc., Q1 2024 Earnings Call, May 06, 2024
Axsome Therapeutics Q1 Loss Widens, Revenue Declines -- Shares Advance Pre-Bell
MT
Axsome: Q1 Earnings Snapshot
AQ
Earnings Flash (AXSM) AXSOME THERAPEUTICS Posts Q1 Revenue $75M, vs. Street Est of $72.9M
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AXSM Stock
  4. News Axsome Therapeutics, Inc.